Trials / Completed
CompletedNCT02601469
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients With Plaque Psoriasis.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Sun Pharmaceutical Industries, Inc. · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
An open label, safety study to assess the potential for adrenal suppression following maximal use treatment with DSXS administered twice daily for 28 days in patients with moderate to severe plaque psoriasis.
Detailed description
1. The objective of this study is to evaluate the potential of DSXS to suppress HPA axis function in patients with moderate to severe plaque psoriasis 2. To evaluate the efficacy parameters, pharmacokinetics and adverse event (AE) profile of DSXS
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DSXS | twice daily for 28 days |
Timeline
- Start date
- 2015-09-04
- Primary completion
- 2016-12-29
- Completion
- 2017-08-25
- First posted
- 2015-11-10
- Last updated
- 2018-12-07
- Results posted
- 2018-12-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02601469. Inclusion in this directory is not an endorsement.